Shares of Gilead Sciences (GILD) are finding support despite bad news on a new drug Wednesday. The stock is rebounding from a pullback to the 10-week moving average. It leaves the biotech leader in a secondary buy range, although a riskier one now that the market is under pressure. It is the second time Gilead has retreated to the line and found support. It also did it in mid-July, a few weeks after it broke out past an 83.80 buy point.